With clin­i­cal tri­als lined up for Zen­tal­is drugs, Chi­na's Zen­tera sets its sights on more deal­mak­ing and an IPO

As Zen­tal­is geared up for an AACR pre­sen­ta­tion of ear­ly da­ta on its WEE1 in­hibitor ear­li­er this year, its Chi­nese joint ven­ture Zen­tera wasn’t idle, ei­ther.

Zen­tera, which has head­quar­ters in Shang­hai, had al­ready nabbed clear­ance to start clin­i­cal tri­als in Chi­na for three of the par­ent com­pa­ny’s drugs. In May — just a month af­ter Zen­tal­is tout­ed three “ex­cep­tion­al re­spons­es” out of 55 pa­tients for their shared lead drug, ZN-c3 — it got a fourth CTA ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER